Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Ovarian Cancer:

Targeted therapy of ovarian cancer including immune check point inhibitor. Kim JY et al. Korean J Intern Med. (2017)

Pathogenesis and heterogeneity of ovarian cancer. Kroeger PT Jr et al. Curr Opin Obstet Gynecol. (2017)

Tumor infiltrating lymphocytes in ovarian cancer. Santoiemma PP et al. Cancer Biol Ther. (2015)

Search results

Items: 1 to 20 of 108138

1.

Calpain system protein expression and activity in ovarian cancer.

Zhang S, Deen S, Storr SJ, Chondrou PS, Nicholls H, Yao A, Rungsakaolert P, Martin SG.

J Cancer Res Clin Oncol. 2018 Nov 17. doi: 10.1007/s00432-018-2794-2. [Epub ahead of print]

PMID:
30448882
2.

Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.

Zhang Q, Wang C, Cliby WA.

Gynecol Oncol. 2018 Nov 15. pii: S0090-8258(18)31415-X. doi: 10.1016/j.ygyno.2018.11.014. [Epub ahead of print]

PMID:
30448260
3.

High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.

Ishikawa M, Nakayama K, Nakamura K, Ono R, Yamashita H, Ishibashi T, Minamoto T, Iida K, Razia S, Ishikawa N, Kyo S.

Hum Pathol. 2018 Nov 15. pii: S0046-8177(18)30424-6. doi: 10.1016/j.humpath.2018.11.001. [Epub ahead of print]

PMID:
30448219
4.

Impact of Chemotherapy-induced Menopause in Women of Childbearing Age With Non-metastatic Breast Cancer - Preliminary Results From the MENOCOR Study.

Passildas J, Collard O, Savoye AM, Dohou J, Ginzac A, Thivat E, Durando X, Kwiatkowski F, Penault-Llorca F, Abrial C, Mouret-Reynier MA.

Clin Breast Cancer. 2018 Oct 23. pii: S1526-8209(18)30373-2. doi: 10.1016/j.clbc.2018.10.003. [Epub ahead of print]

PMID:
30448088
5.

Fertility preserving options for gynecologic malignancies: A review of current understanding and future directions.

McKenzie ND, Kennard JA, Ahmad S.

Crit Rev Oncol Hematol. 2018 Dec;132:116-124. doi: 10.1016/j.critrevonc.2018.09.020. Epub 2018 Oct 4. Review.

PMID:
30447916
6.

Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.

Barreta A, Sarian LO, Ferracini AC, Costa LBE, Mazzola PG, de Angelo Andrade L, Derchain S.

Hum Pathol. 2018 Nov 14. pii: S0046-8177(18)30427-1. doi: 10.1016/j.humpath.2018.10.028. [Epub ahead of print]

PMID:
30447298
7.

INH14, a small-molecule urea derivative, inhibits the IKKα/β-dependent TLR inflammatory response.

Drexel M, Kirchmair J, Santos-Sierra S.

Chembiochem. 2018 Nov 17. doi: 10.1002/cbic.201800647. [Epub ahead of print]

PMID:
30447158
8.

Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study.

Eriksson I, Wettermark B, Bergfeldt K.

Target Oncol. 2018 Nov 16. doi: 10.1007/s11523-018-0604-z. [Epub ahead of print]

PMID:
30446872
9.

Sialic Acid-Dependent Inhibition of T Cells by Exosomal Ganglioside GD3 in Ovarian Tumor Microenvironments.

Shenoy GN, Loyall J, Berenson CS, Kelleher RJ Jr, Iyer V, Balu-Iyer SV, Odunsi K, Bankert RB.

J Immunol. 2018 Nov 16. pii: ji1801041. doi: 10.4049/jimmunol.1801041. [Epub ahead of print]

PMID:
30446565
10.

Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.

Romeo C, Joly F, Ray-Coquard I, El Kouri C, Mercier-Blas A, Berton-Rigaud D, Kalbacher E, Cojocarasu O, Fabbro M, Cretin J, Zannetti A, Abadie-Lacourtoisie S, Mollon D, Hardy-Bessard AC, Provansal M, Blot E, Delbaldo C, Lesoin A, Freyer G, You B.

Gynecol Oncol. 2018 Nov 14. pii: S0090-8258(18)31358-1. doi: 10.1016/j.ygyno.2018.10.043. [Epub ahead of print]

PMID:
30446275
11.

Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.

Kotoula V, Lakis S, Tikas I, Giannoulatou E, Lazaridis G, Papadopoulou K, Manoussou K, Efstratiou I, Papanikolaou A, Fostira F, Vlachos I, Tarlatzis B, Fountzilas G.

Gynecol Oncol. 2018 Nov 14. pii: S0090-8258(18)31417-3. doi: 10.1016/j.ygyno.2018.11.016. [Epub ahead of print]

PMID:
30446274
12.

Alteration of BRCA-1 tumor suppressor gene expression in serous and mucinous ovarian neoplasms in the benign-borderline-malignant pathway.

Yousif HMA, Mohammed RAA.

Curr Probl Cancer. 2018 Nov 6. pii: S0147-0272(18)30275-7. doi: 10.1016/j.currproblcancer.2018.10.003. [Epub ahead of print]

PMID:
30446260
13.

A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.

Guo W, Zhu L, Yu M, Zhu R, Chen Q, Wang Q.

Clin Epigenetics. 2018 Nov 16;10(1):142. doi: 10.1186/s13148-018-0574-0.

PMID:
30446011
14.

Gynecologic assessment of 19 adult females with cartilage-hair hypoplasia - high rate of HPV positivity.

Holopainen E, Vakkilainen S, Mäkitie O.

Orphanet J Rare Dis. 2018 Nov 16;13(1):207. doi: 10.1186/s13023-018-0945-9.

PMID:
30445974
15.

Molecular Mechanisms Regulating Organ-Specific Metastases in Epithelial Ovarian Carcinoma.

Barbolina MV.

Cancers (Basel). 2018 Nov 15;10(11). pii: E444. doi: 10.3390/cancers10110444. Review.

PMID:
30445726
16.

Development of a multiplexed giant magnetoresistive biosensor array prototype to quantify ovarian cancer biomarkers.

Klein T, Wang W, Yu L, Wu K, Boylan KLM, Vogel RI, Skubitz APN, Wang JP.

Biosens Bioelectron. 2018 Oct 23;126:301-307. doi: 10.1016/j.bios.2018.10.046. [Epub ahead of print]

PMID:
30445305
17.

Obesity and Cancer Risk: Emerging biological mechanisms and perspectives.

Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M.

Metabolism. 2018 Nov 13. pii: S0026-0495(18)30232-4. doi: 10.1016/j.metabol.2018.11.001. [Epub ahead of print] Review.

PMID:
30445141
18.

Accelerated Barocycler Lysis and Extraction (ABLE) sample preparation for clinical proteomics by mass spectrometry.

Lucas N, Robinson AB, Marcker Espersen M, Mahboob S, Xavier D, Xue J, Balleine RL, deFazio A, Hains PG, Robinson PJ.

J Proteome Res. 2018 Nov 16. doi: 10.1021/acs.jproteome.8b00684. [Epub ahead of print]

PMID:
30444966
19.

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.

Lin ZP, Zhu YL, Lo YC, Moscarelli J, Xiong A, Korayem Y, Huang PH, Giri S, LoRusso P, Ratner ES.

PLoS One. 2018 Nov 16;13(11):e0207399. doi: 10.1371/journal.pone.0207399. eCollection 2018.

PMID:
30444904
20.

Overexpression of the lncRNA FER1L4 inhibits paclitaxel tolerance of ovarian cancer cells via the regulation of the MAPK signaling pathway.

Liu S, Zou B, Tian T, Luo X, Mao B, Zhang X, Lei H.

J Cell Biochem. 2018 Nov 15. doi: 10.1002/jcb.28032. [Epub ahead of print]

PMID:
30444026

Supplemental Content

Loading ...
Support Center